Delving into the Latest Updates on Novo Nordisk Ltd. with Synapse

Overview

A Multinational, Open Label, Randomised, Three Period, Cross Over Trial Investigating The Impact Of Exercise And Type Of Basal Insulin Used On Blood Glucose Levels In Subjects With Type 1 Diabetes Treated With a Basal Bolus Regimen Using Insulin Detemir, Glargine and NPH as Comparators and Insulin Aspart as Bolus Insulin Levemir® Exercise Study

Start Date14 Mar 2006

Sponsor / Collaborator

Novo Nordisk Ltd.

ISRCTN51125379

/ CompletedPhase 1/2

Treating To Target in Type 2 diabetes

Start Date01 Nov 2004

Sponsor / Collaborator

Novo Nordisk Ltd.

ISRCTN34091554

/ CompletedNot Applicable

A double-blind, randomised, crossover study to investigate the difference in frequency of episodes of hypoglycaemia during treatment with Biphasic Insulin Aspart 30 (NovoMix®30) compared to Biphasic Human Insulin 30 (Mixtard® 30) in patients with well-controlled, type 2 diabetes

Start Date05 Jun 2002

Sponsor / Collaborator

Novo Nordisk Ltd.

100 Clinical Results associated with Novo Nordisk Ltd.

Login to view more data

0 Patents (Medical) associated with Novo Nordisk Ltd.

Login to view more data

79

Literatures (Medical) associated with Novo Nordisk Ltd.

08 Apr 2025·Neurology

Understanding the Experiences of Patients and Dyad Care Partners in Early Alzheimer’s Disease (P11-3.011)

Author: Floegel, Catherine ; Al-Zubeidi, Tamara ; Bottomley, Catherine ; Lv, Lei ; Aly, Abdalla ; Hyde, Richard ; McKee, Stephanie ; Fazio-Eynullayeva, Elnara ; Miller, Jordan ; McKay, Caroline ; Mystowski, Paul

01 Apr 2025·Diabetes Therapy

The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK

Article

Author: Whitaker, Joseph ; MacLellan, Martina ; Malkin, Samuel J P ; Hunt, Barnaby ; Mansinho, Joana Nunes ; Ali, Samina ; Elnaggar, Mohamed ; Glah, Divina

INTRODUCTIONGlucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.METHODSThe published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well as treatment-specific changes in physiological parameters and hypoglycemia rates, were sourced from PIONEER 4. Patients were modeled to receive oral semaglutide or liraglutide until HbA1c exceeded 8.0% (64 mmol/mol), after which treatment was intensified to basal insulin. Annual disutilities associated with treatment administration were applied to capture the differential impact of a once-daily oral versus once-daily injectable medication on quality of life. Costs, expressed in 2022 pounds sterling (GBP), were calculated from a National Health Service (NHS) perspective. The acquisition cost of liraglutide was reduced by up to 50% at increments of 5% across a range of scenarios.RESULTSOral semaglutide was associated with improved quality-adjusted life expectancy of 0.18 quality-adjusted life years versus liraglutide 1.8 mg due to a reduced incidence of diabetes-related complications and a reduced treatment-administration burden. Direct, per-person complication costs were estimated to be GBP 187 lower with oral semaglutide. Oral semaglutide remained dominant or cost-effective in the majority of scenarios, even with liraglutide price reductions of 50% applied.CONCLUSIONSOral semaglutide 14 mg was projected to be cost-effective versus lower-cost liraglutide 1.8 mg in the UK.

14 Mar 2025·ACS Pharmacology & Translational Science

d₄-Cystamine: A Deuterated Cystamine Derivative with Improved Anti-Inflammatory and Anti-Fibrotic Activities in a Murine Model of Fibrosing Steatohepatitis

Article

Author: Kim, Sun ; Ballatore, Carlo ; Dohil, Ranjan ; Monti, Ludovica ; Kim, Andrea ; Momper, Jeremiah D. ; Hartmann, Phillipp ; Reca, Agustina ; Kaufmann, Benedikt ; Tran, Chelsea ; Alle, Thibault ; Feldstein, Ariel E. ; Oukoloff, Killian ; Gertsman, Ilya ; Sung, Hana ; Leszczynska, Aleksandra ; Stoess, Christian ; Lucero, Bobby

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a multifactorial chronic disease that can progress to metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, ultimately leading to liver cirrhosis and hepatocellular carcinoma. Oxidative stress is believed to play an important role in the development of MASH. Small aminothiol compounds such as cysteamine and its oxidized precursor, cystamine, are known pleiotropic compounds that exhibit relatively potent antioxidant and other effects. Herein, we evaluate the efficacy of cystamine, as well as two deuterated derivatives, in a choline-deficient, L-amino acid-defined, high-fat-diet (CDAA-HFD) mouse model of rapidly progressing liver fibrosis. Compared to control mice, daily oral administration of isotopically reinforced cystamine derivatives (200 mg/kg) led to a significant reduction of liver fibrosis and inflammation as well as oxidative stress. Moreover, the efficacy of treatment appeared to increase with the deuteration state of cystamine, with the tetradeuterated derivative, d ₄ -cystamine, being the most effective. These results indicate that deuterated cystamine derivatives hold promise as potential candidates for the treatment of MASH.

100 Deals associated with Novo Nordisk Ltd.

Login to view more data

100 Translational Medicine associated with Novo Nordisk Ltd.

Login to view more data